Dapagliflozin Trial for Renal Protection in Heart Transplant Recipients Initiated
The DAPARHT trial is evaluating dapagliflozin's efficacy in preventing renal function deterioration in heart transplant recipients.
Therapeutic Area
Therapeutic area intelligence for Heart Transplantation with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.